Avastin and Lucentis similarly effective in treating wet age-related macular degeneration. |
|
|
EurekAlert: "Both drugs were highly effective regardless of the approach to dosing," said Daniel F. Martin M.D., study chair for CATT and Chairman of the Cole Eye Institute at the Cleveland Clinic. "There was slightly less vision gain with as-needed treatment. However, patients seeking the small extra advantage of monthly treatment need to be mindful of the additional burden, risks, and costs of monthly injections. Since as-needed dosing required 10 fewer eye injections over the course of two years and yielded similar visual results, many patients may choose this option."
|